Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by whisky11on Mar 16, 2021 1:24pm
179 Views
Post# 32808480

R-107 it's better than spray

R-107 it's better than spray
  • R-107 Transforms Nitric Oxide Into a Practical Therapy: Despite the compelling data demonstrating nitric oxide’s activity against COVID-19 infection, nitric oxide gas is not a practical therapy for use in a pandemic situation. R-107 overcomes the issues with nitric oxide gas, and transforms nitric oxide therapy into a potentially best-of-care treatment for COVID-19 infection – even in a pandemic situation. Unlike nitric oxide, which must be administered as an inhalation therapy, R-107 is a liquid that is readily administered by a single intramuscular injection. Due to its ease of administration, R-107 will allow for thousands of patients to be treated simultaneously, without the need for special delivery equipment or trained respiratory therapists.
  • R-107 Provides Sustained Delivery of Nitric Oxide Over a 24-Hour Period: Unlike nitric oxide, which has a half-life of only a few seconds after being absorbed in the lung, R-107 slowly releases nitric oxide all tissues of the body over 24-hours
  • R-107 Delivers Nitric Oxide Systemically Throughout the Body – Not Just in the Lungs:  After injection, R-107 enters the bloodstream, where it begins to deliver nitric oxide systemically throughout the body, thus allowing the nitric oxide it release to potentially eliminate the SARS-CoV-2 virus in all tissues, not only in the lungs.
<< Previous
Bullboard Posts
Next >>